Influence of glucose and inflammatory cytokines on TGF-beta1 and CTGF mRNA expressions in human peritoneal mesothelial cells
- PMID: 15870892
Influence of glucose and inflammatory cytokines on TGF-beta1 and CTGF mRNA expressions in human peritoneal mesothelial cells
Abstract
Peritoneal fibrosis is a major complication of long-term continuous ambulatory peritoneal dialysis (CAPD) treatment. Transforming growth factor-beta (TGF-beta) has been reported to play an important role in the fibrosis of various tissues by stimulating connective tissue growth factor (CTGF) expression. In order to elucidate the mechanism of CAPD-related peritoneal fibrosis, we studied the influence of high glucose concentrations and inflammatory cytokines on mRNA expressions of TGF-beta and CTGF in cultured human peritoneal mesothelial cells (HPMC). HPMC were isolated from normal omentum and cultured with 0.5 or 1.0% glucose or mannitol for 7 days. TGF-beta1 and CTGF mRNA were quantified by one step real-time reverse transcription-polymerase chain reaction (real-time RT-PCR). TGF-beta1 and CTGF mRNA expression levels were significantly increased (p<0.05) by glucose in a dose-dependent manner, but not by mannitol. The expression levels were correlated between TGF-beta1 and CTGF. Effects of inflammatory cytokines were also examined by adding tumor necrosis factor-alpha (TNF-alpha), interleukin-1 (IL-1) or interleukin-6 (IL-6) to the medium at 0.1 ng/ml for 2 days. TGF-beta1 expression tended to be increased by TNF-alpha and IL-6. On the other hand, CTGF expression was significantly decreased (p<0.01) by IL-1 but not changed by TNF-alpha or IL-6. These results suggest that high glucose concentration may play a central role in peritoneal fibrosis. Responses of TGF-beta1 and CTGF to inflammatory cytokines were not necessarily identical, suggesting that CTGF may be a better therapeutic target for peritoneal fibrosis than TGF-beta1.
Similar articles
-
Inhibition effect of small interfering RNA of connective tissue growth factor on the expression of vascular endothelial growth factor and connective tissue growth factor in cultured human peritoneal mesothelial cells.Chin Med J (Engl). 2007 Feb 5;120(3):231-6. Chin Med J (Engl). 2007. PMID: 17355828
-
Connective tissue growth factor and its regulation in the peritoneal cavity of peritoneal dialysis patients.Kidney Int. 2003 Jul;64(1):331-8. doi: 10.1046/j.1523-1755.2003.00069.x. Kidney Int. 2003. PMID: 12787426
-
Regulation of CCN2/CTGF and related cytokines in cultured peritoneal cells under conditions simulating peritoneal dialysis.Nephrol Dial Transplant. 2009 Feb;24(2):458-69. doi: 10.1093/ndt/gfn524. Epub 2008 Sep 19. Nephrol Dial Transplant. 2009. PMID: 18805993
-
Cytokines and growth factors involved in peritoneal fibrosis of peritoneal dialysis patients.Int J Artif Organs. 2005 Feb;28(2):129-34. doi: 10.1177/039139880502800208. Int J Artif Organs. 2005. PMID: 15770592 Review.
-
Hypothesis: pathogenesis of systemic sclerosis.J Rheumatol. 2003 Apr;30(4):755-9. J Rheumatol. 2003. PMID: 12672195 Review.
Cited by
-
High glucose upregulates connective tissue growth factor expression in human vascular smooth muscle cells.BMC Cell Biol. 2007 Jan 16;8:1. doi: 10.1186/1471-2121-8-1. BMC Cell Biol. 2007. PMID: 17224075 Free PMC article.
-
Proinflammatory Effect of High Glucose Concentrations on HMrSV5 Cells via the Autocrine Effect of HMGB1.Front Physiol. 2017 Sep 29;8:762. doi: 10.3389/fphys.2017.00762. eCollection 2017. Front Physiol. 2017. PMID: 29033853 Free PMC article.
-
MicroRNA-302c modulates peritoneal dialysis-associated fibrosis by targeting connective tissue growth factor.J Cell Mol Med. 2019 Apr;23(4):2372-2383. doi: 10.1111/jcmm.14029. Epub 2019 Jan 28. J Cell Mol Med. 2019. PMID: 30693641 Free PMC article.
-
Fibrosis of Peritoneal Membrane as Target of New Therapies in Peritoneal Dialysis.Int J Mol Sci. 2022 Apr 27;23(9):4831. doi: 10.3390/ijms23094831. Int J Mol Sci. 2022. PMID: 35563220 Free PMC article. Review.
-
Strategies for blocking the fibrogenic actions of connective tissue growth factor (CCN2): From pharmacological inhibition in vitro to targeted siRNA therapy in vivo.J Cell Commun Signal. 2009 Mar;3(1):5-18. doi: 10.1007/s12079-009-0043-9. Epub 2009 Mar 18. J Cell Commun Signal. 2009. PMID: 19294531 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous